Artiva biotherapeutics appoints alison moore, ph.d., to its board of directors

San diego, oct. 22, 2024 (globe newswire) -- artiva biotherapeutics, inc. (nasdaq: artv), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of alison moore, ph.d., as an independent member of its board of directors.
ARTV Ratings Summary
ARTV Quant Ranking